{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:41:14Z","timestamp":1792132874352,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C12292\/A20861"],"award-info":[{"award-number":["C12292\/A20861"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PPRPGM-Nov20\\100002"],"award-info":[{"award-number":["PPRPGM-Nov20\\100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C12292\/A20861"],"award-info":[{"award-number":["C12292\/A20861"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PPRPGM-Nov20\\100002"],"award-info":[{"award-number":["PPRPGM-Nov20\\100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The clinical validity of the multifactorial BOADICEA model for epithelial tubo-ovarian cancer (EOC) risk prediction has not been assessed in a large sample size or over a longer term.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated the model discrimination and calibration in the UK Biobank cohort comprising 199,429 women (733 incident EOCs) of European ancestry without previous cancer history. We predicted 10-year EOC risk incorporating data on questionnaire-based risk factors (QRFs), family history, a 36-SNP polygenic risk score and pathogenic variants (PV) in six EOC susceptibility genes (<jats:italic>BRCA1<\/jats:italic>, <jats:italic>BRCA2<\/jats:italic>, <jats:italic>RAD51C<\/jats:italic>, <jats:italic>RAD51D<\/jats:italic>, <jats:italic>BRIP1<\/jats:italic> and <jats:italic>PALB2<\/jats:italic>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Discriminative ability was maximised under the multifactorial model that included all risk factors (AUC\u2009=\u20090.68, 95% CI: 0.66\u20130.70). This model was well calibrated in deciles of predicted risk with calibration slope=0.99 (95% CI: 0.98\u20131.01). Discriminative ability was similar in women younger or older than 60 years. The AUC was higher when analyses were restricted to PV carriers (0.76, 95% CI: 0.69\u20130.82). Using relative risk (RR) thresholds, the full model classified 97.7%, 1.7%, 0.4% and 0.2% women in the RR\u2009&lt;\u20092.0, 2.0\u2009\u2264\u2009RR\u2009&lt;\u20092.9, 2.9\u2009\u2264\u2009RR\u2009&lt;\u20096.0 and RR\u2009\u2265\u20096.0 categories, respectively, identifying 9.1 of incident EOC among those with RR\u2009\u2265\u20092.0.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>BOADICEA, implemented in CanRisk (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.canrisk.org\">www.canrisk.org<\/jats:ext-link>), provides valid 10-year EOC risks and can facilitate clinical decision-making in EOC risk management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-024-02851-z","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:02:52Z","timestamp":1726671772000},"page":"1473-1479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank"],"prefix":"10.1038","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-3790","authenticated-orcid":false,"given":"Xin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ficorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-1214","authenticated-orcid":false,"given":"Joe","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-4757","authenticated-orcid":false,"given":"Jonathan","family":"Tyrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Pashayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-732X","authenticated-orcid":false,"given":"Paul D. P.","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-3247","authenticated-orcid":false,"given":"Douglas F.","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"2851_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"2851_CR2","unstructured":"Cancer Research UK. Ovarian cance survival2016-2020. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/ovarian-cancer\/survival."},{"key":"2851_CR3","first-page":"937","volume":"93","author":"CA Doubeni","year":"2016","unstructured":"Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93:937\u201344.","journal-title":"Am Fam Physician"},{"key":"2851_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35:151\u20136.","journal-title":"Semin Oncol Nurs"},{"key":"2851_CR5","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182\u201393.","journal-title":"Lancet"},{"key":"2851_CR6","doi-asserted-by":"publisher","first-page":"20170571","DOI":"10.1259\/bjr.20170571","volume":"91","author":"R Kamal","year":"2018","unstructured":"Kamal R, Hamed S, Mansour S, Mounir Y, Abdel Sallam S. Ovarian cancer screening\u2014ultrasound; impact on ovarian cancer mortality. Br J Radiol. 2018;91:20170571.","journal-title":"Br J Radiol"},{"key":"2851_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.amjsurg.2016.06.010","volume":"212","author":"KK Ludwig","year":"2016","unstructured":"Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212:660\u20139.","journal-title":"Am J Surg"},{"key":"2851_CR8","first-page":"565","volume":"5","author":"WH Parker","year":"2009","unstructured":"Parker WH, Jacoby V, Shoupe D, Rocca W. Effect of bilateral oophorectomy on women\u2019s long-term health. Women\u2019s Health. 2009;5:565\u201376.","journal-title":"Women\u2019s Health"},{"key":"2851_CR9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","volume":"91","author":"WA Rocca","year":"2016","unstructured":"Rocca WA, Gazzuola-Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clin Proc. 2016;91:1577\u201389.","journal-title":"Mayo Clin Proc"},{"key":"2851_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/IGC.0000000000000943","volume":"27","author":"PE Tucker","year":"2017","unstructured":"Tucker PE, Cohen PA. Sexuality and risk-reducing salpingo-oophorectomy. Int J Gynecol Cancer. 2017;27:847\u201352.","journal-title":"Int J Gynecol Cancer"},{"key":"2851_CR11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jmedgenet-2022-108471","volume":"59","author":"A Lee","year":"2022","unstructured":"Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S, et al. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence. J Med Genet. 2022;59:1206\u201318.","journal-title":"J Med Genet"},{"key":"2851_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41431-021-00987-7","volume":"30","author":"EO Dareng","year":"2022","unstructured":"Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022;30:349\u201362.","journal-title":"Eur J Hum Genet"},{"key":"2851_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/jmedgenet-2021-107904","volume":"59","author":"A Lee","year":"2022","unstructured":"Lee A, Yang X, Tyrer J, Gentry-Maharaj A, Ryan A, Mavaddat N, et al. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. J Med Genet. 2022;59:632\u201343.","journal-title":"J Med Genet"},{"key":"2851_CR14","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.","journal-title":"PLoS Med"},{"key":"2851_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1136\/jmg-2022-108806","volume":"59","author":"X Yang","year":"2022","unstructured":"Yang X, Eriksson M, Czene K, Lee A, Leslie G, Lush M, et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. J Med Genet. 2022;59:1196\u2013205.","journal-title":"J Med Genet"},{"key":"2851_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr.","year":"1996","unstructured":"Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387.","journal-title":"Stat Med"},{"key":"2851_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/jpm11090916","volume":"11","author":"N Pashayan","year":"2021","unstructured":"Pashayan N, Antoniou AC, Lee A, Wolfson M, Chiquette J, Eloy L, et al. Should age-dependent absolute risk thresholds be used for risk stratification in risk-stratified breast cancer screening? J Pers Med. 2021;11:916.","journal-title":"J Pers Med"},{"key":"2851_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/jmedgenet-2016-103800","volume":"53","author":"R Manchanda","year":"2016","unstructured":"Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of \u2018premenopausal risk-reducing salpingo-oophorectomy\u2019 for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet. 2016;53:591\u20139.","journal-title":"J Med Genet"},{"key":"2851_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2015.10.001","volume":"139","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Legood R, Pearce L, Menon U. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. Gynecol Oncol. 2015;139:487\u201394.","journal-title":"Gynecol Oncol"},{"key":"2851_CR20","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2022."},{"key":"2851_CR21","unstructured":"Cancer Research UK. Ovarian cancer incidence statistics. 2016\u20132018. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer\/incidence#collapseOne."},{"key":"2851_CR22","doi-asserted-by":"crossref","unstructured":"Pavanello M, Chan IH, Ariff A, Pharoah PD, Gayther SA, Ramus SJ. Rare germline genetic variants and the risks of epithelial ovarian cancer. Cancers. 2020;12:3046.","DOI":"10.3390\/cancers12103046"},{"key":"2851_CR23","doi-asserted-by":"crossref","unstructured":"Van Geloven N, Giardiello D, Bonneville EF, Teece L, Ramspek CL, Van Smeden M, et al. Validation of prediction models in the presence of competing risks: a guide through modern methods. BMJ. 2022;377:e069249.","DOI":"10.1136\/bmj-2021-069249"},{"key":"2851_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41591-022-01746-x","volume":"28","author":"RC Fitzgerald","year":"2022","unstructured":"Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N. The future of early cancer detection. Nat Med. 2022;28:666\u201377.","journal-title":"Nat Med"},{"key":"2851_CR25","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","volume":"186","author":"A Fry","year":"2017","unstructured":"Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186:1026\u201334.","journal-title":"Am J Epidemiol"},{"key":"2851_CR26","unstructured":"National Institue for Health and Care Excellence. Ovarian cancer: identifying and managing familial and genetic risk. 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ng241."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02851-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02851-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02851-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T15:11:34Z","timestamp":1730128294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02851-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11,16]]}},"alternative-id":["2851"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02851-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ACA and DFE are named creators of the BOADICEA model, which has been licensed by Cambridge Enterprise (University of Cambridge). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All participants in the UK Biobank provided informed consent. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}